BioInvent International AB logo

BINV BTA - BioInvent International AB News Story

SEK1.7 0.0  0.0%

Last Trade - 12/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £268.8m
Enterprise Value £136.0m
Revenue £11.6m
Position in Universe th / 1832

BRIEF-Bioinvent And Cantargia Sign Manufacturing Agreement For Monoclonal Antibody CAN10

Thu 26th November, 2020 7:36am
Nov 26 (Reuters) - CANTARGIA AB  CANTA.ST :
    * BIOINVENT AND CANTARGIA SIGN MANUFACTURING AGREEMENT FOR
MONOCLONAL ANTIBODY CAN10
    * MAJORITY OF WORK WILL BE COMPLETED IN 2021 TO START
CLINICAL
TRIALS AS EARLY AS POSSIBLE DURING 2022.

Source text for Eikon:  ID:nWkr3JFCfh 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.